Systemic Pharmacokinetics of BOL-303224-A

Conjunctivitis, Bacterial Clinical Trial

Official title:
Systemic Pharmacokinetics of BOL-303224-A After Single and Multiple Instillations of BOL-303224-A in Subjects With Suspected Bacterial Conjunctivitis

Status Completed

Clinical Trial Summary

This is a multi-center, open-label, single dose/multiple dose, pharmacokinetic study in participants with bacterial conjunctivitis. The purpose of this study is to determine the extent of systemic exposure to BOL-303224-A following single and multiple topical administration of BOL-303224-A in participants with suspected bacterial conjunctivitis.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00407589
Study type	Interventional
Source	Bausch & Lomb Incorporated
Contact
Status	Completed
Phase	Phase 1
Start date	October 2006
Completion date	October 2007

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03696342` - Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.	Phase 3
Withdrawn	`NCT03698045` - Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.	Phase 1
Completed	`NCT03987178` - Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists	N/A
Completed	`NCT00357773` - Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis	Phase 3
Completed	`NCT03519516` - Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects	Phase 1
Withdrawn	`NCT01721694` - Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection	Phase 3